A 2009 study using tumor-specific autologous T-cells genetically modified to have a high specificity for melanoma/melanocyte antigens MART-1 or gp100 were generated and administered to 36 patients with metastatic melanoma [6]. The gene discussed is PMEL; the disease is metastatic melanoma.